CBD-Intel

Regulatory briefing

FDA considers the question of routes to market for non-pharma CBD

Written by || 18th June 2019 || Regulatory briefing | Regulation and Legislation | North America United States

The US FDA has confirmed its commitment to creating an alternative route to market for non-pharmaceutical CBD products such as foods and dietary supplements – eventually ...

Restricted content. Do you want to read more?

Read related content from CBD-Intel
FDA’s big meeting leaves long road ahead shrouded in uncertainty
When will CBD foods be legal in the US? Don’t hold your breath
FDA jurisdiction still unchallenged – but industry presses for clarity

Featured topic

The Food and Drug Administration (FDA) rejected applications to use hemp extract as a dietary supplement.

Here are the conclusions we have attracted. CBD-Intel will continue to work on providing answers to the various questions that have arisen.

Blog | Policy and politics | US federal regulation

Sign up to our newsletter

By signing up you agree to our Terms and Conditions